Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
* Promising TG4001 efficacy results presented at ESMO in September 2019
* €54 million in cash and cash equivalents as of September 30, 2019
* Significant news flow confirmed before year-end:
- First efficacy readout of TG4010 in lung cancer expected in December 2019
- myvac(TM): Two clinical trials with TG4050 to start shortly
- Start of clinical trial investigating new route of administration of TG6002
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer